$1.25 +0.03 (%) Galena Biopharma Inc - NASDAQ

May. 6, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Galena Biopharma 2016 Outlook Focuses On 'High Value' Cancer Immunotherapy Pipeline

    Benzinga | Jan. 13, 2016 | 13:37PM EST
  2. Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Uniqure Shares Gain Following Release Of Clinical Trial Data

    Benzinga | Jan. 7, 2016 | 15:02PM EST
  3. Mid-Day Market Update: Finish Line Drops On Weak Results; Dynavax Shares Spike Higher

    Benzinga | Jan. 7, 2016 | 12:03PM EST
  4. Shares Of Galena Biopharma Plunged On Thursday, Company Announces Public Offering

    Benzinga | Jan. 7, 2016 | 10:43AM EST
  5. Mid-Morning Market Update: Markets Open Lower; KB Home Misses Q4 Views

    Benzinga | Jan. 7, 2016 | 09:54AM EST
  6. Midatech Completes Acquisition of Zuplenz from Galena Biopharma

    Benzinga | Dec. 30, 2015 | 04:20AM EST
  7. Midatech Agrees to Acquire Zuplenz from Galena Biopharma for $3.75M Plus Up to $26M in Milestone Payments

    Benzinga | Dec. 18, 2015 | 04:19AM EST
  8. Benzinga's Top Upgrades

    Benzinga | Nov. 12, 2015 | 09:30AM EST
  9. Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting

    Benzinga | Nov. 9, 2015 | 07:17AM EST
  10. Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients

    Benzinga | Sep. 30, 2015 | 07:06AM EST
  11. Galena Biopharma Launches Zuplenz Oral Soluble Film

    Benzinga | Jul. 29, 2015 | 07:06AM EST
  12. Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress

    Benzinga | Jun. 15, 2015 | 07:06AM EST
  13. Monday Morning Movers: Achillion Up, Regulus Down Following Drug Results

    Benzinga | Feb. 9, 2015 | 09:05AM EST
  14. Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society of

    Benzinga | Dec. 8, 2014 | 07:08AM EST
  15. UPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided

    Benzinga | Nov. 20, 2014 | 10:05AM EST
  16. Events for the Week of Nov. 17-21, 2014

    Benzinga | Nov. 17, 2014 | 13:13PM EST
  17. Galena Biopharma Doses First Patient In Phase 2 Clinical Trial With NeuVax In Combination With Herceptin To Treat High-Risk HER2 3+ Or HER2 Gene-Amplified Breast Cancer Patients

    Benzinga | Nov. 11, 2014 | 07:05AM EST
  18. Morning Market Losers

    Benzinga | Nov. 3, 2014 | 09:48AM EST
  19. US Stock Futures Edge Higher Ahead Of Alcoa Earnings, Fed Minutes

    Benzinga | Oct. 8, 2014 | 07:19AM EST
  20. Midday Gainers From Wednesday, August 27

    Benzinga | Aug. 27, 2014 | 14:18PM EST
  21. UPDATE: MLV & Co Reiterates On Galena Biopharma On Positive Long-Term Outlook

    Benzinga | Aug. 27, 2014 | 07:59AM EST
  22. Galena Biopharma Appoints Mark W. Schwartz, Ph.D., As President And CEO

    Benzinga | Aug. 21, 2014 | 07:05AM EST
  23. Morning Market Losers

    Benzinga | Aug. 12, 2014 | 09:51AM EST
  24. Intercept Pharma Soars On Positive Liver Drug Data

    IBD | Aug. 11, 2014 | 22:20PM EST
  25. Markets Open Higher; McDonald's Profit Misses Estimates

    Benzinga | Jul. 22, 2014 | 11:10AM EST
  26. Top Healthcare Movers For June 9, 2014

    Benzinga | Jun. 9, 2014 | 14:27PM EST
  27. Mid-Morning Market Update: Markets Open Higher; Forest Labs To Acquire Furiex For $1.1B In Cash

    Benzinga | Apr. 28, 2014 | 10:22AM EST
  28. Morning Market Movers

    Benzinga | Apr. 28, 2014 | 09:43AM EST
  29. Galena Biopharma Announces Department of Defense Grant for NeuVax Clinical Trial

    Benzinga | Apr. 28, 2014 | 07:06AM EST
  30. Morning Market Losers

    Benzinga | Mar. 18, 2014 | 09:47AM EST
  31. After-Hours Movers for Mar. 17, 2014: FF, GALE Higher, OXBT, EOX, TWER, CHH Lower

    Benzinga | Mar. 17, 2014 | 17:14PM EST
  32. Earnings Scheduled For March 17, 2014

    Benzinga | Mar. 17, 2014 | 04:59AM EST
  33. Mid-Afternoon Market Update: 3D Printing Names Take a Hit From Barron's Piece as Fuel Cell Names Continue Rally

    Benzinga | Mar. 10, 2014 | 15:50PM EST
  34. Mid-Day Market Update: Chiquita Gains On Merger News; Cliffs Natural Shares Drop

    Benzinga | Mar. 10, 2014 | 12:44PM EST
  35. Mid-Morning Market Update: Markets Open Lower; McDonald's Comparable Sales Fall 0.3%

    Benzinga | Mar. 10, 2014 | 10:35AM EST
  36. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr

    Benzinga | Feb. 28, 2014 | 10:40AM EST
  37. UPDATE: Cantor Fitzgerald Downgrades Galena Biopharma

    Benzinga | Feb. 18, 2014 | 12:11PM EST
  38. Sector Gainers And Losers For The Week Ending February 14, 2014

    Benzinga | Feb. 18, 2014 | 11:45AM EST
  39. Morning Market Losers

    Benzinga | Feb. 3, 2014 | 10:05AM EST
  40. Market Wrap For January 17: Stocks Finish Week With Mixed Results

    Benzinga | Jan. 17, 2014 | 16:40PM EST
  41. Top Trending Tickers On StockTwits For January 17

    Benzinga | Jan. 17, 2014 | 10:17AM EST
  42. Galena Biopharma Acquires Mills Pharmaceuticals

    Benzinga | Jan. 13, 2014 | 07:10AM EST
  43. Galena Enrolls First Patient in GALE-301 Cancer Immunotherapy Phase 2 Clinical Trial in Ovarian Cancer

    Benzinga | Jan. 7, 2014 | 07:10AM EST
  44. UPDATE: Oppenheimer Initiates Coverage on Galena Biopharma on NeuVax/Abstral Potential

    Benzinga | Nov. 26, 2013 | 08:41AM EST
  45. Benzinga's Top Initiations

    Benzinga | Nov. 26, 2013 | 07:09AM EST
  46. Galena Biopharma Announces Phase 1 Trial Showa Folate Binding Protein Vaccine is Safe and Immunogenic

    Benzinga | Nov. 11, 2013 | 07:08AM EST
  47. Galena Biopharma Launches Abstral Sublingual Tablets for Treatment of Breakthrough Cancer Pain

    Benzinga | Oct. 3, 2013 | 07:09AM EST
  48. Galena Begins RELIEF Patient Registry for Abstral Sublingual Tablets

    Benzinga | Sep. 3, 2013 | 07:08AM EST
  49. Benzinga's Top Initiations

    Benzinga | Dec. 31, 2012 | 02:47AM EST
  50. UPDATE: Piper Jaffray Initiates Galena Biopharma at Overweight on ImmunoRx Potential

    Benzinga | Dec. 31, 2012 | 01:17AM EST
Trading Center